Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot

Share this content:
Immune checkpoint blockade combined with chemotherapy may sensitize “cold” tumors to immunotherapy and lead to enhanced responses.
Immune checkpoint blockade combined with chemotherapy may sensitize “cold” tumors to immunotherapy and lead to enhanced responses.

Immune checkpoint blockade combined with chemotherapy may sensitize tumors that are not infiltrated by immune cells, which are often referred to as “cold” tumors, to treatment with immune checkpoint blockade, a review article published online in the Annals of Oncology concluded.1

The review authors evaluated data from both preclinical studies and ongoing clinical trials and described the effects of different chemotherapeutic agents and potential value of immunochemotherapy combinations. They also evaluated data based on different dosing schedules.

Although chemotherapeutic agents were originally thought to suppress the immune system, preclinical studies have shown that chemotherapeutic agents actually have immunostimulatory effects, and this property, when combined with immune checkpoint blockade, could improve tumor response to therapy. Chemotherapeutic agents are thought to stimulate the immune system by increasing immunogenicity and T-cell infiltration. Chemotherapies are also thought to boost responses to subsequent therapy because they can hinder immunosuppressive cells and/or promote effector cells.

“Each chemotherapeutic drug impacts the tumor microenvironment differently,” the review authors wrote. “In order to determine the most suitable combination partners for ICB [immune checkpoint blockade], it is crucial to understand these mechanisms.”

The review authors proposed that combining immune checkpoint blockade with different chemotherapeutic agents could improve the immunological features of the tumor microenvironment and in turn, improve tumor response to immunotherapy, resensitizing tumors that have historically been unresponsive. They cautioned that the timing, dose amount, and sequence of certain chemotherapeutic agents and immunotherapeutics is important and could affect outcomes.

“Further studies should focus on determining the optimal drug combinations, sequence effects, and optimal concentration-time profiles in representative preclinical models,” the review authors wrote.

Reference

  1. Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, and Schellens JHM. Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors [published online January 4, 2019]. Ann Oncol. doi: 10.1093/annonc/mdy551

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs